CTI Clinical Trial and Consulting Services (CTI) has entered a collaboration with Galectin Therapeutics for a Phase I trial that will support a potential indication of GR-MD-02 for the treatment of non-alcoholic steatohepatitis (NASH or fatty liver disease) with advanced fibrosis.   The Phase I, multi-center, partially blinded, dose escalation trial will evaluate the safety of GR-MD-02 in subjects with Non-Alcoholic Steatohepatitis (NASH) with Advanced Hepatic Fibrosis, and will be conducted in ...